Assays and sequences for 2019-nCoV (SARS-CoV-2) detection and vaccine development

2019-Novel coronavirus detection with ISO 13485:2016 reagents shipped in 1–2 business days

Obtain 2019-nCoV Kits that include all 4 assays designed by the CDC, and Control plasmids, for detection of 2019-nCoV/SARS-CoV-2. Custom research products and reagents for vaccine development are also available. Our world-wide manufacturing capabilities make IDT uniquely able to provide robust qPCR assays while avoiding contamination issues from synthesis of controls and related gene fragments.

Making 2019-nCoV/SARS-CoV-2 detection reagents available

The US Centers for Disease Control and Prevention (CDC) and Chinese government have sequenced and submitted the coronavirus genome to the US NCBI GenBank® database [1]. The CDC has also designed RT-PCR assays and published a protocol for the detection of 2019-nCoV (2019 Novel Coronavirus, recently designated SARS-CoV-2 by the International Committee on Taxonomy of Viruses) [2,3]. On February 4th, 2020, the FDA issued an Emergency Use Authorization to temporarily expand the use of assays to positively identify the coronavirus [4].

Since these actions, IDT has received inquiries from researchers from around the world who are interested in rapidly obtaining assays and developing vaccines targeting the Wuhan coronavirus (2019-nCoV/SARS-CoV-2). With our world-wide manufacturing capabilities, IDT is uniquely able to provide robust qPCR assays while avoiding contamination issues from synthesis of controls and related gene fragments.

IDT provides the CDC assays* for the identification of virus. The assays are manufactured under ISO 13485:2016 conditions and are available for research use only (RUO). The kits containing these assays include primers and 5’ FAM / 3’ Black Hole Quencher® (BHQ) probes. 2019-nCoV controls** are available separately.

2019-nCoV CDC qPCR Probe Assays

IDT provides 2019-nCoV Kits that include the CDC 2019-nCoV/SARS-CoV-2 published assays in individual tubes. Three of the primer/probe sets in this panel target different locations on the 2019-nCoV/SARS-CoV-2 Nucleocapsid gene (N-gene). These 3 primer/probe sets must be run concurrently with the internal control (4th assay), which targets the human RNase P gene. Altogether, there are 4 qPCR assays per patient sample.

Components are premixed to the CDC recommended working concentration and delivered in IDTE, pH 7.5. Stocked kits are available in 3 reaction sizes of 50, 100, and 500 reactions, with custom sizes available (see section below, Don’t see what you need?). Kits are shipped within 1–2 business days at ambient temperature.

Product Catalog #
2019-nCoV Kit, 50 rxn 10006604
2019-nCoV Kit, 100 rxn 10006605
2019-nCoV Kit, 500 rxn 10006606

Get regional pricing here.

2019-nCoV Plasmid Controls

IDT also provides 2019-nCoV Control plasmids that contain the complete nucleocapsid gene from 2019-nCoV, SARS, or MERS. The 2019-nCoV CDC qPCR Probe Assays target regions within the 2019-nCoV/SARS-CoV-2 nucleocapsid gene, which is present in the 2019-nCoV_N Positive Control plasmid. The Hs_RPP30 Positive Control Kit contains a portion of the RPP30 gene, a single copy gene present in the human genome. Control Plasmids are delivered at 250 µL (200,000 copies/µL) in IDTE, pH 8.0, shipping within 1–2 business days at ambient temperature.

Product Catalog #
2019-nCoV_N Positive Control 10006625
Hs_RPP30 Positive Control 10006626
MERS-CoV Control 10006623
SARS-CoV Control 10006624

Get regional pricing here.

Vaccine development

IDT uses double-stranded DNA fragments to create synthetic proteins designed as safe reagents for vaccine research. IDT offers 3 convenient options: linear gBlocks Gene Fragments, eBlocks Gene Fragments, or Custom Genes cloned into vectors. These sequences are available in varying lengths and synthesis scales. Start your order, and we will help you choose the format that best fits your needs.

Ordering synthetic gene fragments through our dedicated coronavirus channels ensures:

  • Priority shipping
  • Sequence verification
  • Preferred pricing

Place your order here. Upon confirmation of your order, please click the “Sign up” button and include your sales order number in the notes section. A member of our Synthetic Biology Support Team will send a follow-up email confirming that preferred pricing and shipping have been added.

Don’t see what you need?

IDT’s unique manufacturing capabilities allow us to be agile—to quickly respond to special requests. And we are committed to providing those working on the Wuhan coronavirus epidemic with high quality reagents, as fast as possible.

If our current, stocked 2019-nCoV Kits and Controls don’t provide the research tools you need, let’s discuss those requirements.

For custom Wuhan coronavirus research products contact us.

 

CDC information for laboratories

Access the CDC’s latest laboratory guidance for 2019-nCoV RT-PCR assays.

* IDT is not, and does not claim to be, a primary, preferred or recommended source of the CDC coronavirus primer-probe panel.  IDT is independently offering an easy-to-order version of the panel of primer and probe sequences that were published by the CDC for use in coronavirus detection.

** The IDT controls have not been designed, tested, validated by CDC, nor are they in any way endorsed by the CDC or any other public health agency. These controls were independently designed by IDT against the entire nucleocapsid gene of SARS, MERS, and 2019-nCOV. These controls are offered as a convenience to our customers. Controls should be validated by the end-user if used for the interpretation of test results.

References

  1. (2020) 2019 Novel Coronavirus (2019-nCoV), Wuhan, China. [Online] US Centers for Disease Control and Prevention. [Accessed 28 Jan 2020].
  2. (2020) 2019-Novel coronavirus (2019-nCoV) real-time rRT-PCR panel primers and probes. US Centers for Disease Control and Prevention. [Accessed 28 Jan 2020].
  3. (2020) Real-time RT-PCR panel for detection 2019-novel coronavirus. US Centers for Disease Control and Prevention. [Accessed 28 Jan 2020].
  4. (2020) Emergency use authorization. [Online] US Centers for Disease Control and Prevention. [Accessed 28 Jan 2020].

Published Feb 10, 2020